Skip to main content

Expanded Access to Sodium Phenylbutyrate/Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis: Learnings From an ALS Community Partnership

Lead Author: Machelle Manuel, PhD, Head of Global Medical Affairs at Amylyx Pharmaceuticals

Published: Muscular Dystrophy Association (MDA)

Date: March 13 - 16, 2022

Read more (opens new window)

Global Phase 3, Randomized, Placebo-Controlled Trial of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (A35- 004 PHOENIX): Study Design Overview

Lead Author: Leonard H. van den Berg, MD, PhD

Published: International Symposium on ALS-MND (MNDA)

Date: December 8, 2021

Read more (opens new window)

Long-Term Functional Benefits and Safety of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis

Lead Author: Sabrina Paganoni, MD, PhD

Published: International Symposium on ALS-MND (MNDA)

Date: December 7, 2021

Read more (opens new window)

Safety and Biological Activity of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol (PB/TURSO) for the Treatment of Alzheimer's Disease: Results from the Phase 2a PEGASUS Study

Lead Author: Steven E. Arnold, MD

Published: Clinical Trials on Alzheimer’s Disease (CTAD)

Date: November 9 - 12, 2021

Read more (opens new window)

Longer Overall Survival in the CENTAUR Trial: A Rank-Preserving Structural Failure Time Model Adjusts for Crossover From Placebo to Sodium Phenylbutyrate (PB)/Taurursodiol (TURSO)

Lead Author: Sabrina Paganoni, MD, PhD

Published: Northeast ALS Consortium Annual Meeting (NEALS)

Date: October 7, 2021

Read more (opens new window)

Design of a Global Phase 3, Randomized, Placebo-Controlled Trial of a Fixed-Dose Sodium Phenylbutyrate and Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis

Lead Author: Sabrina Paganoni, MD, PhD

Published: Northeast ALS Consortium Annual Meeting (NEALS)

Date: October 6, 2021

Read more (opens new window)

PREVENT: A Randomized, Placebo-Controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia

Lead Author: Colleen M. Craig, MD

Published: The Journal of Clinical Endocrinology & Metabolism

Date: August 1, 2021

Read more (opens new window)

Functional and Survival Benefit of Sodium Phenylbutyrate–Taurursodiol in Amyotrophic Lateral Sclerosis

Lead Author: Sabrina Paganoni, MD, PhD

Published: International Congress on Neuromuscular Diseases (ICNMD)

Date: May 21 - 22, 2021 & May 28 - 29, 2021

Read more (opens new window)

Design of the International, Randomized, Placebo-Controlled Phase 3 PHOENIX Trial of AMX0035 in Amyotrophic Lateral Sclerosis

Lead Author: Leonard H. van den Berg, MD, PhD

Published: European Network to Cure ALS (ENCALS)

Date: May 12 - 14, 2021

Read more (opens new window)

Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS

Lead Author: Sabrina Paganoni, MD, PhD

Published: American Academy of Neurology (AAN)

Date: April 19, 2021

Read more (opens new window)